Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Imatinib Mesylate in Patients With Recurrent Small Cell Lung Cancer

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Completed	18 and over	NCI	NCCTG-N0124 CALGB-30201, N0124, NCT00052949

Trial Description

Purpose:

Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent small cell lung cancer.

Eligibility:

• At least 18 years old
• No more than one previous chemotherapy regimen
• Measurable disease
• More than 3 weeks since chemotherapy or surgery
• More than 2 weeks since radiation therapy
• No previous imatinib mesylate
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive imatinib mesylate by mouth twice a day. Treatment may continue for as long as benefit is shown. Patients will be evaluated periodically for up to 3 years.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

North Central Cancer Treatment Group

Alex Adjei, MD, PhD, Protocol chair(Contact information may not be current)		Ph: 507-284-2511 Email: adjei.alex@mayo.edu

Cancer and Leukemia Group B

Antonius Miller, MD, Protocol chair		Ph: 336-713-4392; 800-446-2255

Registry Information
Official Title		Phase II Trial Of STI571 In Patients With Relapsed Small Cell Lung Cancer
Trial Start Date		2003-05-02
Registered in ClinicalTrials.gov		NCT00052949
Date Submitted to PDQ		2002-09-27
Information Last Verified		2004-08-19
NCI Grant/Contract Number		CA25224

Back to Top